2023
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study
BISOGNO, Gianni, Veronique MINARD-COLIN, Ilaria ZANETTI, Andrea FERRARI, Soledad GALLEGO et. al.Základní údaje
Originální název
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study
Autoři
BISOGNO, Gianni, Veronique MINARD-COLIN, Ilaria ZANETTI, Andrea FERRARI, Soledad GALLEGO, Raquel Davila FAJARDO, Henry MANDEVILLE, Anna KELSEY, Rita ALAGGIO, Daniel ORBACH, van Scheltinga Sheila TERWISSCHA, Gabriela Guillen BURRIEZA, Myriam BEN-ARUSH, Heidi GLOSLI, Peter MÚDRY (203 Česká republika, domácí), Sima FERMAN, Christine DEVALCK, Anne Sophie DEFACHELLES, Johannes Hendrikus Maria MERKS a Meriel JENNEY
Vydání
Journal of clinical oncology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2023, 0732-183X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 45.300 v roce 2022
Kód RIV
RIV/00216224:14110/23:00133412
Organizační jednotka
Lékařská fakulta
UT WoS
001030226300009
Klíčová slova anglicky
Nonmetastatic Rhabdomyosarcoma; Children
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 14. 2. 2024 09:40, Mgr. Tereza Miškechová
Anotace
V originále
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The RMS2005 study included two phase III randomized trials for high-risk (HR) and observational trials for low (LR), standard (SR), and very high-risk (VHR) patients who have been partially reported. Herein, we present a comprehensive report of results achieved for the complete unselected nonmetastatic cohort and analyze the evolution of treatment in comparison with previous European protocols. After a median follow-up of 73.1 months, the 5-year event-free survival (EFS) and overall survival (OS) of the 1,733 patients enrolled were 70.7% (95% CI, 68.5 to 72.8) and 80.4% (95% CI, 78.4 to 82.3), respectively. The results by subgroup: LR (80 patients) EFS 93.7% (95% CI, 85.5 to 97.3), OS 96.7% (95% CI, 87.2 to 99.2); SR (652 patients) EFS 77.4% (95% CI, 73.9 to 80.5), OS 90.6% (95% CI, 87.9 to 92.7); HR (851 patients) EFS 67.3% (95% CI, 64.0 to 70.4), OS 76.7% (95% CI, 73.6 to 79.4); and VHR (150 patients) EFS 48.8% (95% CI, 40.4 to 56.7), OS 49.7% (95% CI, 40.8 to 57.9). The RMS2005 study demonstrated that 80% of children with localized rhabdomyosarcoma could be long-term survivors. The study has established the standard of care across the European pediatric Soft tissue sarcoma Study Group countries with the confirmation of a 22-week vincristine/actinomycin D regimen for LR patients, the reduction of the cumulative ifosfamide dose in the SR group, and for HR disease, the omission of doxorubicin and the addition of maintenance chemotherapy.
Návaznosti
MUNI/A/1395/2022, interní kód MU |
|